

Dexlan

Dexlansoprazole 30 & 60 mg Capsule

Composition:

Dexlan-30: Each capsule contains Dexlansoprazole INN 30 mg as enteric coated pellets.

Dexlan-60: Each capsule contains Dexlansoprazole INN 60 mg as enteric coated pellets.

Indication: Dexlan (Dexlansoprazole) is a proton pump inhibitor used to treat-

1. Healing of all grades of erosive esophagitis
2. Maintaining healing of erosive esophagitis
3. Heart burn associated with non-erosive Gastroesophageal reflux disease (GERD)

Dosage & administration: Dexlan (Dexlansoprazole) capsule is administered orally. The recommended doses of Dexlansoprazole for adults are as follows:

Indication	Recommended Dose	Frequency
Healing of erosive esophagitis	60 mg	Once daily for up to 8 weeks
Maintenance of Healed erosive esophagitis and relief of heartburn	30 mg	Once daily for up to 6 months
Symptomatic Non-Erosive GERD	30 mg	Once daily for 4 weeks

Contraindication: Dexlan (Dexlansoprazole) is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with Dexlansoprazole

Precaution: Patients taking concomitant Warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.

Side Effect: Adverse events are rarely seen; such as diarrhea, abdominal pain, nausea, vomiting, flatulence etc

Drug Interaction: Dexlan (Dexlansoprazole) may interfere with the absorption of drugs for which gastric pH is important for bioavailability (e.g., Ampicillin esters, Digoxin, iron salts, Ketoconazole).

Use in Pregnancy and Lactation: Dexlansoprazole is considered a pregnancy Category B medication. This means that dexlansoprazole is probably safe for use during pregnancy, although the full risks are currently unknown.

Pediatric Use: Safety and effectiveness of Dexlansoprazole in pediatric patients (less than 18 years of age) have not been established.

Geriatric Use: Safety and effectiveness of Dexlansoprazole in geriatric patients is same as Adults.

Overdose: There have been no reports of significant overdose of Dexlansoprazole. It is not expected

to be removed from the circulation by hemodialysis. If an overdose occurs, treatment should be symptomatic and supportive.

Storage condition: Store in a cool and dry place. Keep away from light and out of reach of children.

Presentation:

Dexlan-30: Each commercial box contains 20/30/50/100's capsule of Dexlansoprazole INN 30 mg as enteric coated pellets.

Dexlan-60: Each commercial box contains 20/30/50/100's capsule of Dexlansoprazole INN 60 mg as enteric coated pellets.

Manufactured by:



The IBN SINA Pharmaceutical Industry Ltd.
Shafipur, Gazipur, Bangladesh.